OCGN Jun 2024 3.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:12AM EDT
Loading interactive chart…
- Zacks
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.
- Zacks
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
Ocugen's (OCGN) shares rise significantly in the year-to-date period on positive progress with its promising pipeline candidates.
- GlobeNewswire
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced a positive outcome of the Data and Safety Monitoring Board (DSMB) Review for its Phase 1/2
© 2024 Yahoo. All rights reserved.